Financial reports
10-K
2023 FY
Annual report
29 Feb 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
10-K
2022 FY
Annual report
1 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
10-K
2021 FY
Annual report
1 Mar 22
Current reports
8-K
Other Events
8 Mar 24
8-K
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
29 Feb 24
8-K
Entry into a Material Definitive Agreement
30 Nov 23
8-K
Other Events
27 Nov 23
8-K
Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences
9 Nov 23
8-K
Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
8 Nov 23
8-K
Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
9 Aug 23
8-K
Xenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover
8 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
2 Jun 23
8-K
Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
9 May 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
30 Nov 23
424B5
Prospectus supplement for primary offering
29 Nov 23
424B5
Prospectus supplement for primary offering
23 Jun 22
424B5
Prospectus supplement for primary offering
22 Jun 22
S-8
Registration of securities for employees
2 Jun 22
424B5
Prospectus supplement for primary offering
1 Mar 22
424B5
Prospectus supplement for primary offering
6 Oct 21
FWP
Free writing prospectus
5 Oct 21
424B5
Prospectus supplement for primary offering
4 Oct 21
S-3ASR
Automatic shelf registration
4 Oct 21
Proxies
DEF 14A
Definitive proxy
27 Apr 23
DEF 14A
Definitive proxy
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 21
DEF 14A
Definitive proxy
28 Apr 20
DEF 14A
Definitive proxy
29 Apr 19
DEF 14A
Definitive proxy
27 Apr 18
DEF 14A
Definitive proxy
27 Apr 17
DEF 14A
Definitive proxy
27 Apr 16
DEF 14A
Definitive proxy
30 Mar 15
Other
CT ORDER
Confidential treatment order
1 Sep 20
EFFECT
Notice of effectiveness
15 Jun 20
UPLOAD
Letter from SEC
10 Jun 20
CORRESP
Correspondence with SEC
10 Jun 20
SEC STAFF
SEC staff action: Order
27 Feb 20
SEC STAFF
SEC staff action: Order
6 Feb 20
CT ORDER
Confidential treatment order
11 Sep 19
CT ORDER
Confidential treatment order
11 Sep 19
EFFECT
Notice of effectiveness
16 Aug 19
CORRESP
Correspondence with SEC
13 Aug 19
Ownership
4
Seggern Christopher Von
12 Mar 24
4
SHERRY AULIN
12 Mar 24
4
CHRISTOPHER JOHN KENNEY
12 Mar 24
4
JAMES R. EMPFIELD
12 Mar 24
4
SHERRINGTON ROBIN
12 Mar 24
4
Andrea DiFabio
12 Mar 24
4
IAN MORTIMER
12 Mar 24
4
ELIZABETH A. GAROFALO
11 Mar 24
144
Notice of proposed sale of securities
8 Mar 24
4
SHERRINGTON ROBIN
8 Mar 24